Treace Medical Concepts, Inc.

TMCI Nasdaq SEC CIK 1630627
Follow Treace Medical Concepts Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $48.3M −3.9% vs same quarter last year
Net income −$12.6M +22.9% vs same quarter last year
EPS, diluted −$0.19 +26.9% vs same quarter last year
Operating cash flow −$3.3M +64.2% vs same quarter last year
Revenue by quarter
$68.7M
$52.6M
$47.4M
$50.2M
$62.5M
$47.2M
$45.4M
$48.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$100M$0$100M$200M$300MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$212.7M−$59M
FY24$209.4M−$55.7M
FY23$187.1M−$50M
FY22$141.8M−$43M
FY21$94.4M−$20.6M
FY20$57.4M−$3.7M
FY19$39.4M−$4.3M
FY18--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−50%0%50%100%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2579.8%−25.5%−27.7%
FY2480.4%−26.6%−26.6%
FY2381.2%−27.5%−26.7%
FY2282%−24.6%−30.3%
FY2182.1%−17.5%−21.8%
FY2078.3%1.5%−6.4%
FY1980.6%−9%−10.8%
FY18---
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$29.5M
FY24−$48.8M
FY23−$46M
FY22−$45.5M
FY21−$19.9M
FY20−$5.6M
FY19−$8.9M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Treace Medical Concepts
  • Healthcare median
−100%−75%−50%−25%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearTreace Medical ConceptsHealthcare median
FY25−27.7%−30.6%
FY24−26.6%−47%
FY23−26.7%−58%
FY22−30.3%−80.4%
FY21−21.8%−71.9%
FY20−6.4%−62.2%
FY19−10.8%−46.3%
FY18-−49.6%